Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Australia-based AtCor Medical, a developer and marketer of cardiovascular devices, has signed new agreements to supply SphygmoCor systems and clinical trial support services to two international pharmaceutical companies.
Subscribe to our email newsletter
According to the company, the minimum values of the contracts are $860,000 and $650,000, respectively. These new orders bring the minimum total value of pharmaceutical trial contracts secured by AtCor in the past six months to over $5.7 million.
The SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects that cannot be detected with standard blood pressure monitoring, the company said.
Duncan Ross, CEO of AtCor Medical, said: “Despite global economic head winds, we continue to see relative resiliency in our sector. The new contracts are further evidence of the increasing importance of SphygmoCor as a tool for understanding drug efficacy and mechanism of action in pharmaceutical clinical trials, and reinforce SphygmoCor’s importance as a drug therapy management tool in clinical practice. We look forward to continuing to build mutually beneficial relationships with our expanding list of pharmaceutical trial customers.”